Telratolimod (MEDI 9197)
(Synonyms: MEDI9197; 3M-052) 目录号 : GC33076
Telratolimod (MEDI 9197)是一种有效的toll-like receptor 7(TLR-7)和toll-like receptor 8(TLR-8)的激动剂。
Cas No.:1359993-59-1
Sample solution is provided at 25 µL, 10mM.
Telratolimod (MEDI 9197) is an effective agonist for toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) [1]. TLR is a type of protein that recognizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and is involved in the regulation of the innate immune system [2]. Telratolimod has anti-tumor activity [3].
In vitro, Telratolimod (3μM) stimulated human peripheral blood mononuclear cells (PBMCs) in the culture medium for 24 hours, promoting the production of high levels of Th1-type cytokines, namely IFNγ and IL-12 p70. Telratolimod can inhibit the release of IL-5 by PBMCs stimulated by phytohemagglutinin, thereby causing the deviation of the polyclonal immune response from the Th2 phenotype [3].
In vivo, administration of radiolabeled Telratolimod (0.1, 0.3, and 1mg/kg; single SC injection) in rats showed that Telratolimod induced very low levels of systemic serum TNF-α. Radiolabeled Telratolimod could be detected in plasma and whole blood for at least 14 days and remained at the injection site for at least 28 days. In the mouse melanoma model, a single IT administration of Telratolimod (20μg) could increase the percentage of tumor-infiltrating lymphocytes (TIL), enhance T cell activation, and lead to a qualitative transformation from single-cell factor production to double-cell factor production (IFN-γ and tumor necrosis factor α, TNF-α) [3].
References:
[1] Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12.
[2] Federico S, Pozzetti L, Papa A, et al. Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists[J]. Journal of Medicinal Chemistry, 2020, 63(22): 13466-13513.
[3] Mullins S R, Vasilakos J P, Deschler K, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies[J]. Journal for immunotherapy of cancer, 2019, 7: 1-18.
Telratolimod (MEDI 9197)是一种有效的toll-like receptor 7(TLR-7)和toll-like receptor 8(TLR-8)的激动剂 [1]。TLR是一类识别病原体相关分子模式(PAMPs)和损伤相关分子模式(DAMPs)的蛋白质,参与先天免疫系统的调节 [2]。Telratolimod具有抗肿瘤活性[3]。
在体外, Telratolimod(3μM)在培养基中刺激人类外周血单个核细胞(human PBMCs)24h,促使其产生了高水平的Th1类细胞因子,即IFNγ和IL-12 p70。Telratolimod能抑制由植物血凝素刺激的PBMCs释放IL-5,从而导致多克隆免疫反应偏离Th2型表型[3]。
在体内,在大鼠中施用放射性标记的Telratolimod(0.1、0.3和1mg/kg;单次皮下注射)显示,Telratolimod诱导非常低水平的全身血清TNFα水平。放射性标记的Telratolimod在血浆和全血中可检测到至少14天,保留在注射部位至少28天。在B16-F10 AP 3小鼠黑素瘤模型中,Telratolimod单次IT给药(20μg)可增加肿瘤浸润淋巴细胞(TIL)的百分比,增强T细胞的活化,并导致从单细胞因子产生到双细胞因子产生(IFN-γ和肿瘤坏死因子α,TNF-α)的定性转变[3]。
Cell experiment [1]: | |
Cell lines |
Human PBMCs |
Preparation Method |
2 × 106cells/mL human PBMCs were cultured for 24h at 37 °C with 3μM Telratolimod or DMSO. NK cells were then isolated using an EasySep® Human NK Cell Enrichment Kit (Stemcell). K562 target cells (ECACC,) were loaded for 20min with DELFIA BATDA reagent (Perkin Elmer) at 37 °C, washed 5 times in PBS, 0.1% (v/v) BSA, 2.5mM probenecid (ThermoFisher Scientific) and co-cultured with NK cells for 3h at 37 °C in the presence of 2.5mM probenecid. Killing was assessed in supernatants by DELFIA EuTDA readout (Perkin Elmer). Percent specific killing was calculated from the fluorescence values of ((Sample – (Target cells only – medium) – (NK cells only – medium) – medium) × 100)/(100% lysis – medium). |
Reaction Conditions |
3μM; 24h |
Applications |
Telratolimod stimulated human PBMC cultures, inducing high levels of Th1 cytokines, IFNγ and IL-12 p70. Telratolimod inhibits the release of IL-5 from human PBMC stimulated by PHA, thereby causing the polyclonal immune response to deviate from the Th 2-like phenotype. |
Animal experiment [1]: | |
Animal models |
Male Sprague Dawley rats |
Preparation Method |
Telratolimod and Resiquimod were prepared in sesame oil with 7.5% EtOH (w/w) and citrate buffer, respectively. Telratolimod, Resiquimod, or Vehicle solution were administered via IT or subcutaneous (SC) injection. [14C]-Telratolimod was quantified in rat tissues, whole-blood, and plasma by Quotient Bioresearch Ltd, UK after SC injection. Whole-blood and plasma samples were collected via a tail vein or via cardiac puncture. Plasma samples were taken for direct Quantitative Radiochemical analysis (QRA). Whole-blood samples were taken for oxidation prior to QRA. Distribution of radioactivity in tissues was determined by quantitative whole-body autoradiography (QWBA). Tissue concentrations of radioactivity were determined using calibrated autoradiographic microscales (GE Healthcare). |
Dosage form |
0.1、0.3 and 1mg/kg; single SC injection |
Applications |
Telratolimod induces very low levels of systemic serum TNFα. The radiolabeled Telratolimod can be detected in plasma and whole blood for at least 14 days, and remains at the injection site for at least 28 days. |
References: |
Cas No. | 1359993-59-1 | SDF | |
别名 | MEDI9197; 3M-052 | ||
Canonical SMILES | NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3OCCCCNC(CCCCCCCCCCCCCCCCC)=O | ||
分子式 | C36H59N5O2 | 分子量 | 593.89 |
溶解度 | DMSO : 5 mg/mL (8.42 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.6838 mL | 8.4191 mL | 16.8381 mL |
5 mM | 0.3368 mL | 1.6838 mL | 3.3676 mL |
10 mM | 0.1684 mL | 0.8419 mL | 1.6838 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet